Siga Technologies Inc. (SIGA) Stock Drops 1.24% Despite Broader Market Losses

Siga Technologies Inc. (SIGA) shares dropped 1.24% to $6.36, underperforming the broader market. The company has risen 8.78% over the past month, outpacing the Medical sector and the S&P 500. Analysts expect earnings of $0.13 per share and revenue of $184.36 million for the year, with a Zacks Rank of #3 (Hold) and a Forward P/E ratio of 49.54.

Title: SIGA Technologies Inc. Shares Drop Amid Market Performance

SIGA Technologies Inc. (SIGA), a commercial-stage pharmaceutical company specializing in health security and infectious diseases, saw its shares drop by 1.24% to $6.36 on June 14, 2025. Despite this decline, SIGA has shown strong performance over the past month, rising 8.78% and outperforming both the Medical sector and the S&P 500. Analysts are expecting the company to report earnings of $0.13 per share and revenue of $184.36 million for the fiscal year, with a Zacks Rank of #3 (Hold) and a Forward P/E ratio of 49.54.

The company's lead product, TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus, has been a key driver of its growth. SIGA has also formed a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.

On May 8, 2025, SIGA reported financial results for the three months ended March 31, 2025. The company stated that it has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives. An international sale of approximately $6 million marked the first quarter, and the company received a $26 million IV TPOXX procurement order from the U.S. government in March.

SIGA's leadership has undergone several changes recently. In March 2025, Retired United States Army General John "Jack" Keane was appointed to the Board of Directors. Additionally, Larry Miller was appointed as General Counsel, and Diem Nguyen, Ph.D., MBA, was named as the new Chief Executive Officer. These appointments reflect SIGA's commitment to strategic growth and operational excellence.

Looking ahead, SIGA's focus on health security and its innovative pipeline of products position it as a key player in the biopharmaceutical sector. However, the company's high Forward P/E ratio suggests that investors are cautious about its valuation. Despite this, SIGA's strong performance and strategic partnerships may continue to drive its growth and market position.

# References
[1] https://quantisnow.com/company/SIGA
[2] https://quantisnow.com/company/SIGA